Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2007

View Archived Issues

New therapeutic agents for cancer covered in recent patent literature

Trodusquemine reduces weight, adiposity and improves plasma insulin and leptin in DIO mice

Recent patents disclose novel antiinfective agents

Recent clinical results with new insulin formulations

Mitochondrial voltage-dependent anion channels appear as new targets in cancer therapy

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Algeta initiates clinical dosimetry study with Alpharadin in HRPC patients

Surface Logix evaluates long-acting PDE-5 inhibitors for cardiovascular indications

The Medicines Company reacquires Angiox in Europe

MerLion begins phase I clinical study of antibiotic friulimicin B

Update on Advanced Life Sciences' phase III trial of cethromycin

Positive phase II results for Anesiva's drug candidate Adlea

Maxygen begins phase IIa trial of MAXY-G34 for breast cancer

Pan-PPAR agonist may be beneficial in accelerated atherosclerosis

Studies show favorable pharmacokinetics, reduced costs with CERA

Snapshots of acute and prophylactic treatments for migraine

Clinical trials with natural products in psoriasis

Clinical trials on rhGH formulations reported at ESPE

CYT003-QbG10 shows no treatment effect in atopic dermatitis

Wyeth assumes European marketing and distribution rights for BeneFIX

NICE recommends Tysabri in highly active relapsing remitting MS

Daivobet Scalp gel filed for scalp psoriasis in U.S. and E.U.

EpiCept accelerates clinical trials of EPC-2407 in cancer

Medtronic's ENDEAVOR IV clinical trial meets primary endpoint

Regulatory guidance on pivotal program for Chronocort

Azur licenses FazaClo rights from Avanir

Japanese priority review for Plavix sNDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...